HEMS MEDICATION SECTION

LEVETIRACETAM (INTERFACILITY TRANSFER)

Date: June 9, 2022 Section: 9-52

Levetiracetam Interfacility Transfer

Indications:

Interfacility transport of a patient with seizure activity, Levetiracetam is an antiepileptic treatment of primary generalized tonic-clonic seizures. Levetiracetam IV is initiated at the transferring facility and may be continued during transport by an ALS unit staffed with a Paramedic current with Expanded Scope of Practice training. This treatment is not tobeinitiated by the Expanded Scope of Practice Trained paramedic independently.

Contraindications:

Sensitivity to Levetiracetam

Typical Sending Facility Administration:

Maintain drip per sending facility orders.

Procedure:

Maintain appropriate delivery rate by IV infusion pump. Continuous cardiac monitoring, monitor vital signs every 10 minutes.

Adverse Effects:

Headache, dizziness, drowsiness, weakness

If patient develops adverse reaction contact medical control from sending facility.

**Not in Medication Box

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval: